Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.

Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, Lockton S, Ling N, Singh S.

J Immunol Methods. 2012 Aug 31;382(1-2):177-88. doi: 10.1016/j.jim.2012.06.002. Epub 2012 Jun 9.

PMID:
22691619
[PubMed - indexed for MEDLINE]
Free Article
2.

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.

Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S.

Inflamm Bowel Dis. 2012 Sep;18(9):1628-33. doi: 10.1002/ibd.21919. Epub 2011 Oct 29.

PMID:
22038899
[PubMed - indexed for MEDLINE]
3.

Antibody response to infliximab and its impact on pharmacokinetics can be transient.

Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S.

Am J Gastroenterol. 2013 Jun;108(6):962-71. doi: 10.1038/ajg.2013.12. Epub 2013 Feb 19.

PMID:
23419382
[PubMed - indexed for MEDLINE]
4.

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, van der Kleij D, Gils A, Dijkstra G.

Aliment Pharmacol Ther. 2012 Oct;36(8):765-71. doi: 10.1111/apt.12030. Epub 2012 Aug 28.

PMID:
22928581
[PubMed - indexed for MEDLINE]
5.

Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.

Am J Gastroenterol. 2014 Jul;109(7):1055-64. doi: 10.1038/ajg.2014.106. Epub 2014 May 6.

PMID:
24796769
[PubMed - indexed for MEDLINE]
6.
7.

Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.

Stubenrauch K, Wessels U, Essig U, Vogel R, Schleypen J.

J Pharm Biomed Anal. 2010 Jun 5;52(2):249-54. doi: 10.1016/j.jpba.2009.12.029. Epub 2010 Jan 4.

PMID:
20083366
[PubMed - indexed for MEDLINE]
8.

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.

Imaeda H, Andoh A, Fujiyama Y.

J Gastroenterol. 2012 Feb;47(2):136-43. doi: 10.1007/s00535-011-0474-y. Epub 2011 Sep 28.

PMID:
21953314
[PubMed - indexed for MEDLINE]
9.

Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.

Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Salbato J, Reddy R, McCowen K, Shah S, Lockton S, Chuang E, Singh S.

J Pharm Biomed Anal. 2013 May 5;78-79:39-44. doi: 10.1016/j.jpba.2013.01.031. Epub 2013 Feb 1.

PMID:
23454676
[PubMed - indexed for MEDLINE]
Free Article
10.

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.

Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y.

Gut. 2011 Jan;60(1):41-8. doi: 10.1136/gut.2009.201533. Epub 2010 Jun 2.

PMID:
20519742
[PubMed - indexed for MEDLINE]
11.

Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.

Stubenrauch K, Wessels U, Lenz H.

J Pharm Biomed Anal. 2009 May 1;49(4):1003-8. doi: 10.1016/j.jpba.2009.01.030. Epub 2009 Feb 5.

PMID:
19250787
[PubMed - indexed for MEDLINE]
12.

Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.

Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, Bendtzen K.

Ther Drug Monit. 2013 Aug;35(4):530-8. doi: 10.1097/FTD.0b013e31828d23c3.

PMID:
23765033
[PubMed - indexed for MEDLINE]
13.

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, Díez J, Nagore D, del Agua AR, Moral R, Martin-Mola E, Balsa A.

Ann Rheum Dis. 2012 Dec;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828. Epub 2012 May 6.

PMID:
22563028
[PubMed - indexed for MEDLINE]
14.

Serum infliximab concentrations in pediatric inflammatory bowel disease.

Hämäläinen A, Sipponen T, Kolho KL.

Scand J Gastroenterol. 2013 Jan;48(1):35-41. doi: 10.3109/00365521.2012.741619. Epub 2012 Nov 14.

PMID:
23148710
[PubMed - indexed for MEDLINE]
15.

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Nanda KS, Cheifetz AS, Moss AC.

Am J Gastroenterol. 2013 Jan;108(1):40-7; quiz 48. doi: 10.1038/ajg.2012.363. Epub 2012 Nov 13. Review.

PMID:
23147525
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.

Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T.

World J Gastroenterol. 2014 May 7;20(17):5031-5. doi: 10.3748/wjg.v20.i17.5031.

PMID:
24833846
[PubMed - in process]
Free PMC Article
17.

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.

Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OØ, Ainsworth MA.

Inflamm Bowel Dis. 2012 Dec;18(12):2209-17. doi: 10.1002/ibd.22910. Epub 2012 Feb 16.

PMID:
22344964
[PubMed - indexed for MEDLINE]
18.

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S; ABIRISK consortium.

Gut. 2014 Aug;63(8):1258-64. doi: 10.1136/gutjnl-2013-305259. Epub 2013 Sep 16.

PMID:
24041539
[PubMed - indexed for MEDLINE]
19.

Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study.

Adişen E, Aral A, Aybay C, Gürer MA.

J Dermatol. 2010 Aug;37(8):708-13. doi: 10.1111/j.1346-8138.2010.00882.x.

PMID:
20649712
[PubMed - indexed for MEDLINE]
20.

A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.

Corstjens PL, Fidder HH, Wiesmeijer KC, de Dood CJ, Rispens T, Wolbink GJ, Hommes DW, Tanke HJ.

Anal Bioanal Chem. 2013 Sep;405(23):7367-75. doi: 10.1007/s00216-013-7154-0. Epub 2013 Jul 9.

PMID:
23836086
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk